iBio

iBio

Using artificial intelligence to efficiently and consistently delivers antibody candidates against difficult targets.

  • Edit
Get premium to view all results
DateInvestorsAmountRound
N/A

€0.0

round
N/A

€0.0

round
N/A

€0.0

round
N/A

€0.0

round
investor

€0.0

round
N/A

€0.0

round
N/A

€0.0

round
N/A

€0.0

round
N/A

€0.0

round
*
N/A

$6.2m

Post IPO Equity
Total Funding000k

Financials

Estimates*

Get premium to view all results
Edit
Revenues, earnings & profits over time
USD2021202220232024202520262027
Revenues0000000000000000000000000000
% growth45 %1 %--48 %(20 %)-
EBITDA0000000000000000000000000000
% EBITDA margin(1306 %)(1918 %)-(6676 %)---
Profit0000000000000000000000000000
% profit margin(979 %)(2111 %)-(11070 %)(5131 %)(6749 %)-
EV0000000000000000000000000000
EV / revenue00.0x00.0x00.0x00.0x00.0x00.0x00.0x
EV / EBITDA00.0x00.0x00.0x00.0x00.0x00.0x00.0x
R&D budget0000000000000000000000000000
R&D % of revenue421 %744 %-2304 %---

Source: Company filings or news article, Equity research estimates

Notes (0)
More about iBio
Made with AI
Edit

iBio, Inc. is a biotechnology company leveraging artificial intelligence and computational biology to create next-generation antibody therapeutics. The company's primary focus is on developing medicines for cardiometabolic diseases, obesity, and difficult-to-treat cancers. It has shifted from a contract manufacturing model to concentrating on its proprietary drug discovery pipeline. The core of its operation is an antibody discovery platform that uses machine learning and 3D modeling to identify promising drug targets and design precision antibodies. This integrated technology stack aims to improve the safety and effectiveness of treatments while reducing development timelines.

Founded in 2008 as iBioPharma, Inc., through a merger involving assets from Integrated BioPharma, the company initially centered on its plant-based FastPharming® System for biologics production. A significant strategic pivot moved the company away from contract development and manufacturing services (CDMO) to prioritize its own therapeutic pipeline, particularly in immuno-oncology and cardiometabolic diseases. The company is publicly traded on the NYSE American under the ticker IBIO and is headquartered in San Diego, California. Leadership includes William D. (Chip) Clark as Chairman and Dr. Martin Brenner as CEO and Chief Scientific Officer.

iBio’s business strategy revolves around advancing its preclinical pipeline and forming strategic collaborations. The company’s technology portfolio includes several key components: an AI-driven Epitope Engineering Engine, a proprietary human antibody library, the StableHu™ antibody optimizer, the EngageTx™ T-cell engager panel, and the ShieldTx® antibody masking technology. These tools are applied to develop candidates like IBIO-101 for solid tumors and new treatments for obesity that aim to preserve muscle mass. Revenue has recently been modest, reflecting the company's transition to an R&D-focused model with significant investment in research activities.

Keywords: antibody discovery, artificial intelligence, biotechnology, immuno-oncology, cardiometabolic disease, biopharmaceuticals, drug development, precision medicine, therapeutic pipeline, epitope engineering

Analytics
Unlock the full power of analytics with a premium account
Track company size and historic growth
Track team composition and strength
Track website visits and app downloads

Tech stack

Group
Tech stackLearn more about the technologies and tools that this company uses.
Book a Demo

Investments by iBio

Edit
RubrYc Therapeutics
ACQUISITION by iBio Sep 2022